ERBB2 and cancer: For the 19 patients experiencing active OB within 1 month prior to anti-cancer therapy, 14 patients (73.7%) received intravenous systemic anticancer regimens, including mFOLFOX6 regimen (n = 7), mFLOT regimen (n = 2), mFOLFOX6 plus trastuzumab for Her-2 positive patients (n = 2), mFOLFOX6 plus programmed death receptor 1 (PD-1) antibody sintilimab for 1 dMMR patient and PD-1 antibody monotherapy for the other 2 dMMR patients (1 chose pembrolizumab and 1 chose sintilimab).